Interesting: Heart Failure With Preserved Ejection Fraction Expert Panel Report https://t.co/bWaQp0h7qD #HFpEF
RT @DCRINews: This insightful new paper on #heartfailure is the result of a recent #DCRIThinkTank that brought together experts from academ…
@jtheywood @ajaysmd @RajeevCMohan
Are we still not really talking about LA diastolic dysfunction as a sub population of HFpEF https://t.co/cB4t9eq5kD
RT @JACCJournals: Should clinical trial inclusion criteria in HFpEF address all HFpEF similarly by incl a broad group of subjects (as done…
Surely, surely subpopulations! Has the last decade or so of neutral trials taught us nothing?
Should clinical trial inclusion criteria in HFpEF address all HFpEF similarly by incl a broad group of subjects (as done traditionally in HFrEF)? Or is a narrower approach needed focusing on individual subpopulations (e.g. PVD associated w/ HFpEF)? https:/
How should a classification scheme for #HFpEF be derived?https://t.co/CCSUUO64mN #JACCHF Should it be based on:
RT @DukeHFDoc: Really nice overview of critical challenges in HfpEF led by @DrKishanParikh https://t.co/28CL1gXt6e
RT @doctorheart00: La insuficiencia cardiaca de gasto preservado es una entidad que requiere de investigación académica para mejorar la sob…
Great work from an old friend @DrKishanParikh summarizing current knowledge gaps in our understanding of #HFpEF. All HF is not equal...
Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. https://t.co/JwS10UcRll
RT @doctorheart00: La insuficiencia cardiaca de gasto preservado es una entidad que requiere de investigación académica para mejorar la sob…
RT @doctorheart00: La insuficiencia cardiaca de gasto preservado es una entidad que requiere de investigación académica para mejorar la sob…
La insuficiencia cardiaca de gasto preservado es una entidad que requiere de investigación académica para mejorar la sobrevida de los pacientes. https://t.co/vpyf2NcbXU
RT @paomorejon: • #HeartFailure With Preserved EF Expert Panel Report Current Controversies and Implications for Clinical Trials Great revi…
RT @paomorejon: • #HeartFailure With Preserved EF Expert Panel Report Current Controversies and Implications for Clinical Trials Great revi…
RT @JACCJournals: We challenged leading #HFpEF clinicians, researchers, #industry, #NIH, and #FDA: What are the current controversies in HF…
RT @paomorejon: • #HeartFailure With Preserved EF Expert Panel Report Current Controversies and Implications for Clinical Trials Great revi…
RT @JACCJournals: Is HFpEF a single entity? https://t.co/CCSUUO64mN #JACCHF
RT @JJheart_doc: Steps toward understanding heart failure with preserved ejection fraction. Expert Panel in JACC HF. #DCRIThinkTank @mghhe…
RT @JACCJournals: We challenged leading #HFpEF clinicians, researchers, #industry, #NIH, and #FDA: What are the current controversies in HF…
Is HFpEF a single entity? https://t.co/CCSUUO64mN #JACCHF
RT @paomorejon: • #HeartFailure With Preserved EF Expert Panel Report Current Controversies and Implications for Clinical Trials Great revi…
RT @JACCJournals: We challenged leading #HFpEF clinicians, researchers, #industry, #NIH, and #FDA: What are the current controversies in HF…
We miss you Luke!! @bswhealth_DFW @ivguerrerom @SusanJosephMD
RT @drwaynefranklin: RT @coconnormd: JACC-HF : First expert panel report on HFpEF: Future directions in a condition without a specific ther…
RT @JACCJournals: We challenged leading #HFpEF clinicians, researchers, #industry, #NIH, and #FDA: What are the current controversies in HF…
RT @JACCJournals: We challenged leading #HFpEF clinicians, researchers, #industry, #NIH, and #FDA: What are the current controversies in HF…
RT @JACCJournals: We challenged leading #HFpEF clinicians, researchers, #industry, #NIH, and #FDA: What are the current controversies in HF…
RT @JACCJournals: We challenged leading #HFpEF clinicians, researchers, #industry, #NIH, and #FDA: What are the current controversies in HF…
RT @JACCJournals: We challenged leading #HFpEF clinicians, researchers, #industry, #NIH, and #FDA: What are the current controversies in HF…
RT @JACCJournals: We challenged leading #HFpEF clinicians, researchers, #industry, #NIH, and #FDA: What are the current controversies in HF…
RT @JACCJournals: We challenged leading #HFpEF clinicians, researchers, #industry, #NIH, and #FDA: What are the current controversies in HF…
RT @DukeHFDoc: Really nice overview of critical challenges in HfpEF led by @DrKishanParikh https://t.co/28CL1gXt6e
RT @JJheart_doc: Steps toward understanding heart failure with preserved ejection fraction. Expert Panel in JACC HF. #DCRIThinkTank @mghhe…
RT @JACCJournals: We challenged leading #HFpEF clinicians, researchers, #industry, #NIH, and #FDA: What are the current controversies in HF…
RT @JACCJournals: We challenged leading #HFpEF clinicians, researchers, #industry, #NIH, and #FDA: What are the current controversies in HF…
RT @JTLLERGO: Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Tria…
RT @JACCJournals: We challenged leading #HFpEF clinicians, researchers, #industry, #NIH, and #FDA: What are the current controversies in HF…
RT @JACCJournals: We challenged leading #HFpEF clinicians, researchers, #industry, #NIH, and #FDA: What are the current controversies in HF…
RT @DukeHFDoc: Really nice overview of critical challenges in HfpEF led by @DrKishanParikh https://t.co/28CL1gXt6e
RT @DukeHFDoc: Really nice overview of critical challenges in HfpEF led by @DrKishanParikh https://t.co/28CL1gXt6e
RT @coconnormd: JACC-HF : First expert panel report on HFpEF: Future directions in a condition without a specific therapy https://t.co/67v…
RT @coconnormd: JACC-HF : First expert panel report on HFpEF: Future directions in a condition without a specific therapy https://t.co/67v…
RT @JJheart_doc: Steps toward understanding heart failure with preserved ejection fraction. Expert Panel in JACC HF. #DCRIThinkTank @mghhe…
Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials #HeartFailure https://t.co/64gNGIopqo
RT @coconnormd: JACC-HF : First expert panel report on HFpEF: Future directions in a condition without a specific therapy https://t.co/67v…
RT @paomorejon: • #HeartFailure With Preserved EF Expert Panel Report Current Controversies and Implications for Clinical Trials Great revi…
RT @DCRINews: This insightful new paper on #heartfailure is the result of a recent #DCRIThinkTank that brought together experts from academ…
RT @CarolynMArias: Congrats to @DrKishanParikh, @DukeHFDoc and collaborators for their Expert Panel Report published in @JACCJournals. The…
RT @CarolynMArias: Congrats to @DrKishanParikh, @DukeHFDoc and collaborators for their Expert Panel Report published in @JACCJournals. The…
RT @paomorejon: • #HeartFailure With Preserved EF Expert Panel Report Current Controversies and Implications for Clinical Trials Great revi…
RT @CarolynMArias: Congrats to @DrKishanParikh, @DukeHFDoc and collaborators for their Expert Panel Report published in @JACCJournals. The…
RT @DCRINews: This insightful new paper on #heartfailure is the result of a recent #DCRIThinkTank that brought together experts from academ…
RT @JJheart_doc: Steps toward understanding heart failure with preserved ejection fraction. Expert Panel in JACC HF. #DCRIThinkTank @mghhe…
RT @JTLLERGO: Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Tria…
RT @coconnormd: JACC-HF : First expert panel report on HFpEF: Future directions in a condition without a specific therapy https://t.co/67v…
RT @JJheart_doc: Steps toward understanding heart failure with preserved ejection fraction. Expert Panel in JACC HF. #DCRIThinkTank @mghhe…
RT @paomorejon: • #HeartFailure With Preserved EF Expert Panel Report Current Controversies and Implications for Clinical Trials Great revi…
RT @JJheart_doc: Steps toward understanding heart failure with preserved ejection fraction. Expert Panel in JACC HF. #DCRIThinkTank @mghhe…
RT @DukeHFDoc: Really nice overview of critical challenges in HfpEF led by @DrKishanParikh https://t.co/28CL1gXt6e
RT @paomorejon: • #HeartFailure With Preserved EF Expert Panel Report Current Controversies and Implications for Clinical Trials Great revi…
RT @JJheart_doc: Steps toward understanding heart failure with preserved ejection fraction. Expert Panel in JACC HF. #DCRIThinkTank @mghhe…
RT @JJheart_doc: Steps toward understanding heart failure with preserved ejection fraction. Expert Panel in JACC HF. #DCRIThinkTank @mghhe…
RT @coconnormd: JACC-HF : First expert panel report on HFpEF: Future directions in a condition without a specific therapy https://t.co/67v…
RT @DCRINews: This insightful new paper on #heartfailure is the result of a recent #DCRIThinkTank that brought together experts from academ…
This insightful new paper on #heartfailure is the result of a recent #DCRIThinkTank that brought together experts from academia, industry, and government.
RT @JTLLERGO: Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Tria…
RT @coconnormd: JACC-HF : First expert panel report on HFpEF: Future directions in a condition without a specific therapy https://t.co/67v…
RT @JJheart_doc: Steps toward understanding heart failure with preserved ejection fraction. Expert Panel in JACC HF. #DCRIThinkTank @mghhe…
RT @coconnormd: JACC-HF : First expert panel report on HFpEF: Future directions in a condition without a specific therapy https://t.co/0fH0HMpgBB
RT @paomorejon: • #HeartFailure With Preserved EF Expert Panel Report Current Controversies and Implications for Clinical Trials Great revi…
RT @coconnormd: JACC-HF : First expert panel report on HFpEF: Future directions in a condition without a specific therapy https://t.co/67v…
Congrats to @DrKishanParikh, @DukeHFDoc and collaborators for their Expert Panel Report published in @JACCJournals. The first #DCRIThinkTank I attended...inspiring to see the passion and expertise diff. stakeholders brought to the discussion. https://t.co/
RT @coconnormd: JACC-HF : First expert panel report on HFpEF: Future directions in a condition without a specific therapy https://t.co/67v…
RT @JJheart_doc: Steps toward understanding heart failure with preserved ejection fraction. Expert Panel in JACC HF. #DCRIThinkTank @mghhe…
RT @paomorejon: • #HeartFailure With Preserved EF Expert Panel Report Current Controversies and Implications for Clinical Trials Great revi…
RT @JJheart_doc: Steps toward understanding heart failure with preserved ejection fraction. Expert Panel in JACC HF. #DCRIThinkTank @mghhe…
Steps toward understanding heart failure with preserved ejection fraction. Expert Panel in JACC HF. #DCRIThinkTank @mghhearthealth @baiminstitute @DCRINews @accintouch @jaccjournals https://t.co/5T6JMWrTF2
RT @paomorejon: • #HeartFailure With Preserved EF Expert Panel Report Current Controversies and Implications for Clinical Trials Great revi…
RT @coconnormd: JACC-HF : First expert panel report on HFpEF: Future directions in a condition without a specific therapy https://t.co/67v…
Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials https://t.co/JkBzhYjmhd https://t.co/axqrhbYo9o
RT @coconnormd: JACC-HF : First expert panel report on HFpEF: Future directions in a condition without a specific therapy https://t.co/67v…
RT @JTLLERGO: Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Tria…
RT @DukeHFDoc: Really nice overview of critical challenges in HfpEF led by @DrKishanParikh https://t.co/28CL1gXt6e
RT @JTLLERGO: Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Tria…
RT @coconnormd: JACC-HF : First expert panel report on HFpEF: Future directions in a condition without a specific therapy https://t.co/67v…
RT @coconnormd: JACC-HF : First expert panel report on HFpEF: Future directions in a condition without a specific therapy https://t.co/67v…
RT @DukeHFDoc: Really nice overview of critical challenges in HfpEF led by @DrKishanParikh https://t.co/28CL1gXt6e
RT @DukeHFDoc: Really nice overview of critical challenges in HfpEF led by @DrKishanParikh https://t.co/28CL1gXt6e